Literature DB >> 10966548

Enhanced prognostic stratification of patients with left ventricular hypertrophy with the use of single-photon emission computed tomography.

A M Amanullah1, D S Berman, X Kang, I Cohen, G Germano, J D Friedman.   

Abstract

BACKGROUND: Patients with left ventricular hypertrophy (LVH) are at increased risk of future cardiovascular events. Little is known about risk stratification of these patients with the use of myocardial perfusion imaging. This study sought to assess the prognostic stratification of patients with LVH by using myocardial perfusion single-photon emission computed tomography (SPECT). METHODS AND
RESULTS: We studied 633 consecutive patients with electrocardiographic evidence of LVH who underwent dual isotope myocardial perfusion SPECT (rest thallium 201/stress technetium 99m sestamibi) and were followed up for a mean period of 22 +/- 7 months. During the follow-up period, 67 events (35 cardiac deaths and 32 nonfatal myocardial infarctions) occurred (6% annual event rate). The results of the perfusion scan significantly risk-stratified the population; patients with normal scans had a low rate of nonfatal myocardial infarction and cardiac death (<1% per year of follow-up). The rates of cardiac events increased significantly as a function of the scan result: 4.9% in patients with mildly abnormal scans and 10. 3% in moderately to severely abnormal scans. Cox proportional hazards analysis demonstrated that after adjusting for pretest likelihood of coronary artery disease (the most predictive clinical variable; chi(2) = 15.5, P <.001), summed stress score (the most predictive nuclear variable; chi(2) = 18, P <.0001) added significant incremental prognostic information (global chi(2) increased from 15.5 to 36; P <.001).
CONCLUSIONS: In patients with LVH with an overall high cardiac event rate, SPECT provided enhanced stratification by adding significant incremental prognostic information over clinical and historic variables.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10966548     DOI: 10.1067/mhj.2000.108833

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

Review 1.  Prognostic value of gated myocardial perfusion SPECT.

Authors:  Leslee J Shaw; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

2.  Prognostic implications of stress Tc-99m tetrofosmin myocardial perfusion imaging in patients with left ventricular hypertrophy.

Authors:  Abdou Elhendy; Arend F L Schinkel; Ron T van Domburg; Jeroen J Bax; Harm H H Feringa; Peter G Noordzij; Olaf Schouten; Don Poldermans
Journal:  J Nucl Cardiol       Date:  2007-07       Impact factor: 5.952

Review 3.  Clinical imaging for prevention: directed strategies for improved detection of presymptomatic patients with undetected atherosclerosis--Part I: Clinical imaging for prevention.

Authors:  Leslee J Shaw; Daniel S Berman; Roger S Blumenthal; Matthew J Budoff; Tracy L Faber; Tauqir Goraya; Sandra S Halliburton; Harvey Hecht; Hosen Kiat; Wolfgang Koenig; Shaista Malik; Michael Merhige; Khurram Nasir; James K Min; James O'Keefe; Donna M Polk; Paolo Raggi; Jeffrey A Rosenblatt; Ronald G Schwartz; Allen J Taylor; Gregory S Thomas; William Wijns
Journal:  J Nucl Cardiol       Date:  2008 Jan-Feb       Impact factor: 5.952

4.  Prognostic value of myocardial perfusion SPECT versus exercise electrocardiography in patients with ST-segment depression on resting electrocardiography.

Authors:  Andrea De Lorenzo; Rory Hachamovitch; Xingping Kang; Heidi Gransar; Maria G Sciammarella; Sean W Hayes; John D Friedman; Ishac Cohen; Guido Germano; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2005 Nov-Dec       Impact factor: 5.952

5.  Prognostic value of myocardial perfusion scintigraphy in elderly patients with hypertension: a 10-year follow-up analysis.

Authors:  Luca Nai Fovino; Giorgio Saladini; Anna Rita Cervino; Francesca Saladini; Michele Gregianin; Renato Razzolini; Laura Evangelista
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-15       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.